<ul><li>Helsinki-based biotech company Avenue Biosciences has raised €2.3 million in a seed financing round led by Voima Ventures.</li><li>The funding will be used to accelerate the development of Avenue Biosciences' platform for efficient protein production.</li><li>The technology aims to shorten development times and lower costs for critical therapies, making them more accessible to patients globally.</li><li>Avenue Biosciences plans to launch the commercial sales of the platform in Q4.</li></ul>

Helsinki-based Avenue Biosciences raises €2.3 million to scale AI-enhanced protein engineering

Discover more